Friday, December 6, 2019
This conference has already taken place.
Description
HCL is a rare hematologic malignancy characterized by high risk for infections. Tremendous progress in the management of patients with this disease has resulted in high response rates and improved survival. Yet many patients will relapse or be unresponsive to the initial induction therapy and may require additional treatment.
Hairy cell leukemia is rare, accounting for about 1,000 new cases each year. Because HCL is rare, many physicians may encounter a limited number of patients with this disease throughout their career.
There are four primary professional practice gaps that will be addressed in this educational activity:
First, the physicians may have limited experience in retreating patients if the patients relapse or don’t respond to first-line therapy.
Second, they may also have limited experience in diagnosing variant HCL and distinguishing it from the classic form of HCL.
Third, they may have even less experience in managing HCL in the event of life-threatening complications or serious life-threatening infections and pancytopenia.
Fourth, most physicians will have limited experience in treating patients with a new drug that was approved by the FDA in September 2018 for adult patients with relapsed or refractory HCL.
The speakers in this educational activity will illustrate novel therapies and major challenges in hairy cell leukemia through research and case-based presentations, and will update physicians on new treatments and recommendations.
Agenda
7:00 am Registration and Breakfast
7:30 am Welcome and Introduction
7:40 am Biological Features of Hairy Cell Leukemia and Their Clinical Implications - Dr. Enrico Tiacci, Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia, Italy
8:15 am Management of Classic Hairy Cell Leukemia and Its Complications - Dr. Michael Grever, The Ohio State University Comprehensive Cancer Center-The James, USA
8:50 am Safe and Effective Use of Moxetumomab Pasudotox for Patients with Relapsed and Refractory Hairy Cell Leukemia - Dr. Robert J. Kreitman, National Institutes of Health, USA
9:25 am Challenges in Management of Variant Hairy Cell Leukemia - Dr. Claire Dearden, The Royal Marsden Hospital, UK
10:00 am Q&A and Concluding Remarks
For pricing information, see pricing tab below.
Dates and Times
Start: 12/6/2019 12:00 AM
End: 12/6/2019 12:00 AM
Objectives
Upon completion of this activity, participants should be better able to:
• Describe how to manage rare complications associated with hairy cell leukemia
• Outline how to make a correct diagnosis of HCL and distinguish classic HCL from variant HCL
• Identify the correct time to initiate therapy
• Name new options for management of care when patients relapse or fail to respond to therapy
• Outline how to manage patients with pancytopenia and active infections
• Describe the pathogenesis of HCL and its targetable genetic lesions
Pricing
Tier | Price |
---|---|
This is a free Friday Satellite Symposium preceding the 61st ASH Annual Meeting and Exposition. | $0.00 |
Speakers
Location
Orange County Convention Center
9800 International Dr
Room W307
Orlando, FL 32819
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME®) through the joint providership of The Ohio State University and Hairy Cell Leukemia Foundation. The Ohio State University is accredited by the ACCME® to provide continuing medical education for physicians.
AMA Credit Designation Statement
The Ohio State University designates this live activity for a maximum of 4.00 AMA PRA Category 1 Credit(s) ™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.